

Chapter 15: Congenital Rubella Syndrome

Tatiana Lanzieri, MD; Susan Redd; Emily Abernathy, MS; Joseph Icenogle, PhD

I. Disease Description

Congenital rubella syndrome (CRS) is an illness in infants that results from maternal infection with rubella virus during pregnancy. When rubella infection occurs during early pregnancy, serious consequences—such as miscarriages, stillbirths, and a constellation of severe birth defects in infants can result. The risk of congenital infection and defects is highest during the first 12 weeks of gestation and decreases after the 12th week of gestation; defects are rare after infection in the 20th week (or later) of gestation.^{1–3} Common congenital defects of CRS include cataracts, congenital heart disease, hearing impairment, and developmental delay. Infants with CRS often present with more than 1 sign or symptom consistent with congenital rubella infection. However, infants may present with a single defect, with hearing impairment being the most common single defect. See Chapter 14 (<https://www.cdc.gov/vaccines/pubs/surv-manual/chpt14-rubella.html>), “Rubella,” for more information on rubella infection.

II. Background

The link between congenital cataracts and maternal rubella infection was first made in 1941 by an Australian ophthalmologist, Norman Gregg, who had noticed an unusual number of infants with cataracts following a rubella epidemic in 1940.⁴ In the absence of vaccination, rubella is an endemic disease with epidemics occurring every 6–9 years. If rubella infections occurred among nonimmune pregnant women, CRS cases occurred also. During the 1962–1965 global rubella pandemic, an estimated 12.5 million rubella cases occurred in the United States, resulting in 2,000 cases of encephalitis, 11,250 therapeutic or spontaneous abortions, 2,100 neonatal deaths, and 20,000 infants born with CRS.⁵

In 1969, live attenuated rubella vaccines were licensed in the United States. The goal of the rubella vaccination program was and continues to be prevention of congenital rubella infections, including CRS.⁵ In 2004, an independent panel of internationally recognized experts in public health, infectious diseases, and immunizations reviewed the available data on rubella epidemiology and unanimously agreed that rubella elimination (i.e., the absence of year-round endemic transmission) had been achieved in the United States.⁶ During 2005–2015, the number of reported cases of CRS in the United States declined dramatically to <1 case per year (Centers for Disease Control and Prevention [CDC], unpublished data). Among the 8 CRS cases that occurred during this time, all but 1 were known importations (CDC, unpublished data). Of the 40 CRS cases occurring during 1998–2015, the mother was born outside the United States in 35 (88%).

Although rubella has been eliminated in the United States, it continues to be endemic in many parts of the world. It is estimated that more than 100,000 infants worldwide are born with CRS each year.⁷ According to a survey of the member countries in the World Health Organization (WHO), the number of countries that have incorporated rubella-containing vaccines into their routine national immunization programs increased from 83 in 1996 to 148 (76%) of countries in 2016. As of December 2016, the WHO Region of the Americas and the European Region have established rubella elimination goals, verified by the Region of the Americas in 2015.⁸ The South-East Asia region has a rubella/CRS reduction goal (95%) by 2020;⁹ the Western Pacific Region has established a rubella elimination target without a specific date; and the Eastern Mediterranean and African Regions do not currently have elimination targets. In 2011, WHO recommended that all countries providing 2 doses of measles vaccine, that have not introduced rubella vaccine, consider including rubella-containing vaccine in their immunization program.¹⁰ The United States elimination of rubella and CRS was reconfirmed in 2011 and maintenance of elimination was reported in 2014.^{9,11}



III. Maintenance of Elimination

The United States has established and achieved the goal of eliminating CRS and the indigenous transmission of rubella. As noted above, elimination of endemic rubella was documented and verified in the United States in 2004.⁶ However, because of international travel and countries without routine rubella vaccination, imported cases of rubella and CRS cases still occur. To maintain elimination, the United States should continue to maintain high vaccination rates among children; ensure that women of childbearing age, particularly women in the United States who were born outside of the United States, are vaccinated; and maintain effective surveillance for both rubella and CRS.

IV. Vaccination

See Chapter 14 (<https://www.cdc.gov/vaccines/pubs/surv-manual/chpt14-rubella.html>), “Rubella,” for information on vaccination with rubella-containing vaccines.

V. Case Definition

Case definition for case classification

The following case definition for CRS was approved by the Council of State and Territorial Epidemiologists (CSTE) and published in 2009.¹²

Suspected: An infant who does not meet the criteria for a probable or confirmed case but who has 1 or more of the following findings:

- cataracts,
- congenital glaucoma,
- congenital heart disease (most commonly patent ductus arteriosus or peripheral pulmonary artery stenosis),
- hearing impairment,
- pigmentary retinopathy,
- purpura,
- hepatosplenomegaly,
- jaundice,
- microcephaly,
- developmental delay,
- meningoencephalitis, or
- radiolucent bone disease.

Probable: An infant who does not have laboratory confirmation of rubella infection but has at least 2 of the following, without a more plausible etiology:

- cataracts or congenital glaucoma,
- congenital heart disease (most commonly patent ductus arteriosus or peripheral pulmonary artery stenosis),
- hearing impairment, or
- pigmentary retinopathy;

OR

An infant who does not have laboratory confirmation of rubella infection but has at least 1 or more of the following, without a more plausible etiology:

- cataracts or congenital glaucoma,
- congenital heart disease (most commonly patent ductus arteriosus or peripheral pulmonary artery stenosis),
- hearing impairment, or
- pigmentary retinopathy;

AND 1 or more of the following:

- purpura,
- hepatosplenomegaly,
- microcephaly,
- developmental delay,
- meningoencephalitis, or
- radiolucent bone disease.

Confirmed: An infant with at least one of the symptoms clinically consistent with congenital rubella syndrome listed above, and laboratory evidence of congenital rubella infection demonstrated by:

- isolation of rubella virus, or
- detection of rubella-specific immunoglobulin M (IgM) antibody, or
- infant rubella antibody level that persists at a higher level and for a longer period of time than expected from passive transfer of maternal antibody (i.e., rubella titer that does not drop at the expected rate of a two-fold decline per month), or
- a specimen that is PCR-positive for rubella virus.

Infection only: An infant without any clinical symptoms or signs of rubella but with laboratory evidence of infection demonstrated by:

- isolation of rubella virus, or
- detection of rubella-specific immunoglobulin M (IgM) antibody, or
- infant rubella antibody level that persists at a higher level and for a longer period of time than expected from passive transfer of maternal antibody (i.e., rubella titer that does not drop at the expected rate of a two-fold decline per month), or
- a specimen that is PCR-positive for rubella virus.

Comment: In probable cases, either or both of the eye-related findings (cataracts and congenital glaucoma) should be considered as a single complication. In cases classified as infection only, if any compatible signs or symptoms (e.g., hearing impairment) are identified later, the case is reclassified as confirmed.

Epidemiologic classification of internationally imported and US-acquired

Congenital rubella syndrome cases will be classified epidemiologically as internationally imported or US-acquired, according to the source of infection in the mother, using the definitions below, which parallel the classifications for rubella cases.

Internationally imported case: To be classified as an internationally imported CRS case, the mother must have acquired rubella infection outside the United States or in the absence of documented rubella infection, the mother was outside the United States during at least some of the period when she may have had exposure to rubella that affected her pregnancy (from 21 days before conception and through the first 24 weeks of pregnancy).

US-acquired case: A US-acquired case is one in which the mother acquired rubella from an exposure in the United States. US-acquired cases are subclassified into 4 groups as described in the rubella case classification section in Chapter 14 (<https://www.cdc.gov/vaccines/pubs/surv-manual/chpt14-rubella.html>), “Rubella.”

Note: Internationally imported, import-linked, and imported-virus cases are considered collectively to be import-associated cases.

States may also choose to classify cases as “out-of-state-imported” when imported from another state in the United States. For national reporting, however, cases will be classified as either internationally imported or US-acquired.

VI. Laboratory Testing

Diagnostic tests used to confirm CRS include serologic assays and detection of rubella virus.

For additional information on laboratory testing for rubella virus, see Chapter 14 (<https://www.cdc.gov/vaccines/pubs/surv-manual/chpt14-rubella.html>), “Rubella.” For additional information on use of laboratory testing in surveillance of vaccine-preventable diseases, see Chapter 22 (<https://www.cdc.gov/vaccines/pubs/surv-manual/chpt22-lab-support.html>), “Laboratory Support for the Surveillance of Vaccine-Preventable Diseases.”

Virus detection (real-time RT-PCR, RT-PCR)

Rubella virus can be detected from nasal, throat, urine, and blood specimens from infants with CRS. Efforts should be made to obtain clinical specimens for virus isolation from infants at the time of the initial investigation (see Appendix 15, <https://www.cdc.gov/vaccines/pubs/surv-manual/appx/appendix15-rubella.pdf>). However, because infants with CRS may shed virus from the throat and urine for a prolonged period (sometimes up to a year or even longer), specimens obtained later may also yield rubella virus.

As with rubella infection, molecular typing is recommended because it provides important information to track the epidemiology of rubella in the United States now that rubella virus no longer continuously circulates in this country. By comparing virus sequences from new case-patients with virus sequences from other cases, the origin of particular virus types in this country can be tracked.¹³ Furthermore, this information may help in documenting the maintenance of the elimination of endemic rubella virus transmission. Specimens for molecular typing should be obtained from patients with CRS as soon as possible after diagnosis. Appropriate specimens include throat swabs, urine, and cataracts from surgery. Specimens for virus detection and molecular typing should be sent to CDC or a reference laboratory as directed by the state health department.

Serologic testing

The serologic tests available for laboratory confirmation of CRS infections vary among laboratories. Enzyme immunoassays (EIAs) are the most commonly used and widely available diagnostic test for rubella immunoglobulin G (IgG) and M (IgM) antibodies. EIAs are sensitive and relatively easy to perform. EIA is the preferred testing method for IgM, using the capture technique, although indirect assays are also acceptable. In infants with CRS, IgM antibody can be detected in the infant’s cord blood or serum and persists for about 6 months. Suspect CRS cases which are IgM negative at birth should have this result confirmed at 1 month of age.

Specimen collection

Specimen collection and shipping are important steps in obtaining laboratory diagnosis or confirmation for vaccine preventable diseases. Guidelines have been published for specimen collection and handling for microbiologic agents (<https://stacks.cdc.gov/view/cdc/7590>). Information is also available on using CDC laboratories as support for reference and disease surveillance (<https://www.cdc.gov/ncezid/dsr/specimen-management-branch.html>); this includes

- a central website for requesting lab testing (<https://wwwdev.cdc.gov/laboratory/specimen-submission/index.html>);
- the form required for submitting specimens to CDC (See Appendix 23, Form # CDC 50.34 <https://www.cdc.gov/laboratory/specimen-submission/form.html>);
- information on general requirements for shipment of etiologic agents (Appendix 24, <https://www.cdc.gov/vaccines/pubs/surv-manual/appx/appendix24-etiological-agent.pdf>)—although written to guide specimen submission to CDC, this information may be applicable to submission of specimens to other laboratories; and
- the CDC Infectious Diseases Laboratories Test Directory (<https://www.cdc.gov/laboratory/specimen-submission/list.html>), which not only contains a list of orderable tests for that institution, but also detailed information on appropriate specimen types, collection methods, specimen volume, and points of contact.

The APHL/CDC Vaccine Preventable Disease Reference Centers (https://www.aphl.org/programs/infectious_disease/Documents/ID_VPDQuickReferenceGuide_updated62016.pdf) can perform real-time RT-PCR and genotyping for rubella.

Specific instructions for specimen collection and shipping may be obtained from the CDC rubella website (<https://www.cdc.gov/rubella/lab/specimen-collection-shipment.html>) or by contacting the CDC Viral Vaccine Preventable Diseases Branch at 404-639-4557. Specimens for virus isolation should be sent to CDC as directed by the State Health Department.

For additional information on use of laboratory testing for surveillance of vaccine-preventable diseases, see Chapter 22, “Laboratory Support for the Surveillance of Vaccine-Preventable Diseases.”

VII. Reporting and Case Notification

Case reporting within a jurisdiction

Each state and territory has regulations or laws governing the reporting of diseases and conditions of public health importance.¹⁴ These regulations and laws list the diseases to be reported and describe those persons or groups responsible for reporting, such as healthcare providers, hospitals, laboratories, schools, daycare and childcare facilities, and other institutions. Persons reporting should contact the state health department for state-specific reporting requirements. The *Congenital Rubella Syndrome Case Report Worksheet* is included as Appendix 17 (<https://www.cdc.gov/vaccines/pubs/surv-manual/appx/appendix17-rubella-syn.pdf>), to serve as a guide for data collection during investigation of reported cases.

Case notification to CDC

Provisional notifications of CRS cases should be sent by the state health department to the CDC or directly to Susan Redd at NCIRD, CDC by telephone: 404-639-8763 or by e-mail (SBR1@cdc.gov). Notifications should be sent to the National Notifiable Diseases Surveillance System (NNDSS) using event code 10370. Reporting should not be delayed because of incomplete information or lack of laboratory confirmation; following completion of case investigations, data previously submitted to NNDSS should be updated with the available new information.

The *Congenital Rubella Syndrome Case Report worksheet* (Appendix 17 <https://www.cdc.gov/vaccines/pubs/surv-manual/appx/appendix17-rubella-syn.pdf>) is used to collect clinical and laboratory information on cases of CRS that are reported by state and local health departments. CRS cases are classified by year of patient’s birth.

The following data are epidemiologically important and should be collected in the course of case investigation. Additional information may also be collected at the direction of the state health department.

- Demographic information
 - Name
 - Address
 - Age
 - Sex
 - Ethnicity
 - Race
 - Country of birth (mother)
 - Length of time in United States (mother)
- Reporting source
 - County
 - Earliest date reported
- Clinical
 - Symptoms or syndromes
 - Cataracts
 - Hearing impairment
 - Developmental delay
 - Type of congenital heart defect
 - Pigmentary retinopathy

- Purpura
- Radiolucent bone disease
- Hepatosplenomegaly
- Meningoencephalitis
- Microcephaly
- Other
- Outcome (infant survived or died)
 - Date of death
 - Postmortem examination results
 - Death certificate diagnoses
- Laboratory (performed on both mother and infant)
 - Virus isolation
 - Genotype
 - PCR results
- Maternal history
 - Dates of rubella vaccinations
 - Number of doses of vaccine given
 - If not vaccinated, reason
 - Country of vaccination
 - History of documentation of rubella infection or disease during pregnancy
 - Rubella laboratory results
 - History of pregnancies within and outside the United States (including country and years of pregnancies)
- Travel outside the U.S. during pregnancy (countries visited with dates)
- Contact with foreign travelers during pregnancy
- Epidemiologic
 - Transmission setting
 - Source of transmission (e.g., age, vaccination status, relationship to decedent)
 - Source of exposure
 - Travel history

VIII. Case Investigation

Cases of US-acquired CRS are sentinel events indicating the presence of rubella infections in a community that may have been previously unrecognized. The diagnosis of a single case of US-acquired CRS in a community should result in intensified rubella and CRS surveillance and an investigation to determine where the mother was exposed to rubella. If the mother was exposed in a different state, state health officials should contact the other state to alert public health officials to possible rubella circulation.

Infants with CRS may present with various manifestations of the syndrome, depending on timing of the infection in pregnancy. Infants born to women infected with rubella during pregnancy should be evaluated for infection and CRS. However, depending on the gestational age of the infant at the time of the mother's infection, symptoms may not be apparent after 20 weeks' gestation; the only defect may be hearing impairment. Furthermore, some children are infected in utero but have no congenital defects.

Laboratory confirmation should be sought in all suspected CRS cases, regardless of signs or symptoms.

IX. Conducting active surveillance

Surveillance for CRS should be implemented when confirmed or probable rubella cases are documented in a setting where pregnant women might have been exposed.¹⁵ Women who contract rubella while pregnant should be monitored for birth outcome, and appropriate testing should be performed on the infant after birth. Healthcare providers should be advised to evaluate infants born with conditions consistent with CRS and to collect specimens for virus detection and to perform a rubella-specific IgM antibody test on infants suspected of having CRS.

Streamlining reporting using electronic methods

Although many surveillance systems still rely on paper and pencil for data collection, use of data from sources such as electronic medical records, electronic case reporting, and clinical laboratory information systems (LIMS) can significantly improve reporting speed, enhance data quality, and reduce workload.^{16–22}

X. Prevent Transmission from Infants with CRS

Cases of US-acquired rubella have occurred among susceptible persons providing care for infants with CRS.²³ Because infants can shed the virus for prolonged periods, (up to 1 year of age or longer) infants with CRS should be considered infectious until they are at least 1 year old or until 2 clinical specimens obtained 1 month apart are negative for rubella virus by RT-PCR, either real-time or conventional; culture is also acceptable. The majority of infants will shed virus for 3 months after birth, so screening will typically start at 3 months after a decline would reasonably be expected. Infants with CRS should be placed in contact isolation during any hospital admission before 1 year of age or until the infant is no longer considered infectious. In addition, health officials should consider excluding infants with CRS from child care facilities until he or she is no longer considered infectious. Persons having contact with infants with CRS should have documented evidence of immunity to rubella (see Chapter 14 (<https://www.cdc.gov/vaccines/pubs/surv-manual/chpt14-rubella.html>), “Rubella”) and caregivers of infants with CRS should be aware of the potential hazard of the infants to susceptible pregnant contacts.

References

1. Peckham CS. Clinical and laboratory study of children exposed in utero to maternal rubella. *Arch Dis Child* 1972;47(254):571–77. doi: 10.1136/adc.47.254.571
2. Webster WS. Teratogen update:congenital rubella. *Teratology* 1998;58(1):13–23. doi: 10.1002/(SICI)1096-9926(199807)58:1<13:AID-TERA5>3.0.CO;2-2
3. Miller E, Cradock-Watson JE, Pollock TM. Consequences of confirmed maternal rubella at successive stages of pregnancy. *Lancet* 1982;2(8302):781–4. doi: 10.1016/S0140-6736(82)92677-0
4. Gregg NM. Congenital cataract following german measles in the mother. *Epidemiol Infect* 1991;107(1):3–14. doi: 10.1017/S0950268800048627
5. National Communicable Disease Center. Rubella surveillance. Bethesda, MD: U.S. Department of Health, Education, and Welfare; 1969.
6. CDC. Elimination of rubella and congenital rubella syndrome—United States, 1969–2004. *MMWR Morb Mortal Wkly Rep* 2005;54(11):279–82. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5411a5.htm>
7. Robertson SE, Featherstone DA, Gacic-Dobo M, Hersh BS. Rubella and congenital rubella syndrome: global update. *Rev Panam Salud Publica* 2003;14(5):306–15. doi: 10.1590/S1020-49892003001000005
8. PAHO. Americas region is declared the world’s first to eliminate rubella [press release]. Washington, DC; 2015 April 25. http://www.paho.org/hq/index.php?option=com_content&view=article&id=10798%3A2015-americas-free-of-rubella&catid=740%3Apress-releases&Itemid=1926&lang=pt
9. WHO. Rubella and congenital rubella syndrome control and elimination—global progress, 2000–2014. *Wkly Epidemiol Rec* 2015;90(39):510–6.

10. WHO. Rubella vaccines: WHO position paper. *Wkly Epidemiol Rec* 2011;86(29):301–16.
11. CDC. Documentation and verification of measles, rubella and congenital rubella syndrome elimination in the Region of the Americas: United States national report 2012. Atlanta, GA: CDC; 2012. <https://stacks.cdc.gov/view/cdc/21191>
12. CSTE. Public health reporting and national notification for congenital rubella syndrome. CSTE position statement 09-ID-61. Atlanta, GA: CSTE; 2009. <http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/09-ID-61.pdf>
13. Abernathy E, Chen MH, BeraJ, et al. Analysis of whole genome sequences of 16 strains of rubella virus from the United States, 1961–2009. *Virol J* 2013;10:32. doi: 10.1186/1743-422X-10-32
14. Roush S, Birkhead G, Koo D, Cobb A, Fleming D. Mandatory reporting of diseases and conditions by health care professionals and laboratories. *JAMA* 1999;282(2):164–70. doi: 10.1001/jama.282.2.164
15. CDC. Control and prevention of rubella: evaluation and management of suspected outbreaks, rubella in pregnant women, and surveillance for congenital rubella syndrome. *MMWR Recomm Rep* 2001;50(RR-12):1–23. <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5012a1.htm>
16. CDC. Progress in improving state and local disease surveillance—United States, 2000–2005. *MMWR Morb Mortal Wkly Rep* 2005;54(33):822–5. <https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5433a3.htm>
17. CSTE. Improving public health practice by enhancing the public health community’s capability for electronic information exchange using HL7 CDA. CSTE position statement 13-SI-03. Atlanta, GA: CSTE; 2013. <http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PS/13-SI-03.pdf>
18. CSTE. Common data structure for national notifiable diseases. CSTE position statement 15-EB-01. Atlanta, GA: CSTE; 2015. <http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/2015PS/2015PSFinal/15-EB-01a.pdf>
19. Smith PF, Hadler JL, Stanbury M, Rolfs RT, Hopkins RS; CSTE Surveillance Strategy Group. “Blueprint version 2.0”: updating public health surveillance for the 21st century. *J Public Health Manag Pract* 2013;19(3):231–9. doi: 10.1097/PHH.0b013e318262906e
20. CSTE. Review of and recommendations for the National Notifiable Disease Surveillance System: a state and local health department perspective. Atlanta, GA: CSTE; 2013. http://c.ymcdn.com/sites/www.cste.org/resource/resmgr/PDFs/NNDSS_Report.pdf
21. CSTE. 2004–2010 national assessments of electronic laboratory reporting in health departments: findings and recommendations [assessment brief]. Atlanta, GA: CSTE; 2012. <http://www.cste2.org/webpdfs/elrassessmentbrief.pdf>
22. Mac Kenzie WR, Davidson AJ, Wiesenthal A, et al. The promise of electronic case reporting. *Public Health Rep* 2016;131(6):742–46. doi: 10.1177/0033354916670871
23. Greaves WL, Orenstein WA, Stetler HC, Preblud SR, Hinman AR, Bart KJ. Prevention of rubella transmission in medical facilities. *JAMA* 1982;248(7):861–4. doi: 10.1177/0033354916670871